These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
462 related articles for article (PubMed ID: 26905396)
21. Annual report: Surveillance of adverse events following immunisation in Australia, 2011. Mahajan D; Cook J; Dey A; Macartney K; Menzies RI Commun Dis Intell Q Rep; 2012 Dec; 36(4):E315-32. PubMed ID: 23330706 [TBL] [Abstract][Full Text] [Related]
22. Acceptability of Internet adverse event self-reporting for pandemic and seasonal influenza immunization among health care workers. Lapphra K; Dobson S; Bettinger JA Vaccine; 2010 Aug; 28(38):6199-202. PubMed ID: 20654668 [TBL] [Abstract][Full Text] [Related]
23. Web-based intensive monitoring of adverse events following influenza vaccination in general practice. van Balveren-Slingerland L; Kant A; Härmark L Vaccine; 2015 May; 33(19):2283-2288. PubMed ID: 25797367 [No Abstract] [Full Text] [Related]
24. A scoping review of active, participant-centred, digital adverse events following immunization (AEFI) surveillance: A Canadian immunization research network study. Psihogios A; Brianne Bota A; Mithani SS; Greyson D; Zhu DT; Fung SG; Wilson SE; Fell DB; Top KA; Bettinger JA; Wilson K Vaccine; 2022 Jul; 40(31):4065-4080. PubMed ID: 35680501 [TBL] [Abstract][Full Text] [Related]
25. Annual report: surveillance of adverse events following immunisation in Australia, 2009. Mahajan D; Roomiani I; Gold MS; Lawrence GL; McIntyre PB; Menzies RI Commun Dis Intell Q Rep; 2010 Sep; 34(3):259-76. PubMed ID: 21090181 [TBL] [Abstract][Full Text] [Related]
26. Adverse events following HPV vaccination, Alberta 2006-2014. Liu XC; Bell CA; Simmonds KA; Svenson LW; Russell ML Vaccine; 2016 Apr; 34(15):1800-5. PubMed ID: 26921782 [TBL] [Abstract][Full Text] [Related]
27. [Reported adverse events following influenza vaccination]. van Balveren-Slingerland L; Rümke HC; Kant AC Ned Tijdschr Geneeskd; 2014; 158():A6841. PubMed ID: 24518843 [TBL] [Abstract][Full Text] [Related]
28. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety. Alicino C; Merlano C; Zappettini S; Schiaffino S; Della Luna G; Accardo C; Gasparini R; Durando P; Icardi G Hum Vaccin Immunother; 2015; 11(1):91-4. PubMed ID: 25483520 [TBL] [Abstract][Full Text] [Related]
29. Events supposedly attributable to vaccination or immunization during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean. Ropero-Álvarez AM; Whittembury A; Bravo-Alcántara P; Kurtis HJ; Danovaro-Holliday MC; Velandia-González M Vaccine; 2015 Jan; 33(1):187-92. PubMed ID: 25444798 [TBL] [Abstract][Full Text] [Related]
30. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System. Woo EJ; Moro PL; Cano M; Jankosky C Vaccine; 2017 Oct; 35(42):5618-5621. PubMed ID: 28886946 [TBL] [Abstract][Full Text] [Related]
31. Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England. de Lusignan S; Dos Santos G; Correa A; Haguinet F; Yonova I; Lair F; Byford R; Ferreira F; Stuttard K; Chan T BMJ Open; 2017 May; 7(5):e015469. PubMed ID: 28515198 [TBL] [Abstract][Full Text] [Related]
32. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS. Halsey NA; Griffioen M; Dreskin SC; Dekker CL; Wood R; Sharma D; Jones JF; LaRussa PS; Garner J; Berger M; Proveaux T; Vellozzi C; ; Broder K; Setse R; Pahud B; Hrncir D; Choi H; Sparks R; Williams SE; Engler RJ; Gidudu J; Baxter R; Klein N; Edwards K; Cano M; Kelso JM Vaccine; 2013 Dec; 31(51):6107-12. PubMed ID: 24120547 [TBL] [Abstract][Full Text] [Related]
33. Trends in Adverse Event Reporting Before and After the Introduction of the Med Safety App in Nigeria. Elemuwa UG; Bitrus F; Oreagba IA; Osakwe AI; Abiodun AS; Onu K; Abubakar A; Faniyi AE; Etuk V; Yuah D; Momodu R; Adeyeye CM Pharmaceut Med; 2024 May; 38(3):251-259. PubMed ID: 38705932 [TBL] [Abstract][Full Text] [Related]
34. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16. Bricout H; Chabanon AL; Souverain A; Sadorge C; Vesikari T; Caroe TD Euro Surveill; 2017 May; 22(18):. PubMed ID: 28494843 [TBL] [Abstract][Full Text] [Related]
35. A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy. Regan AK; Tracey LE; Blyth CC; Richmond PC; Effler PV Vaccine; 2016 Apr; 34(20):2299-304. PubMed ID: 27038132 [TBL] [Abstract][Full Text] [Related]
36. Vaccine safety. Labadie J Int J Risk Saf Med; 2011; 23(2):113-5. PubMed ID: 21673419 [TBL] [Abstract][Full Text] [Related]
37. Surveillance of adverse events following immunization in China: Past, present, and future. Liu D; Wu W; Li K; Xu D; Ye J; Li L; Wang H Vaccine; 2015 Jul; 33(32):4041-6. PubMed ID: 25936727 [TBL] [Abstract][Full Text] [Related]
38. Enhanced passive surveillance of influenza vaccination in England, 2016-2017- an observational study using an adverse events reporting card. de Lusignan S; Ferreira F; Damaso S; Byford R; Pathirannehelage S; Yeakey A; Yonova I; Schuind A; Dos Santos G Hum Vaccin Immunother; 2019; 15(5):1048-1059. PubMed ID: 30648923 [TBL] [Abstract][Full Text] [Related]
39. Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: results from a feasibility study. Stuurman AL; Verstraeten T; De Schryver A Expert Rev Vaccines; 2017 Feb; 16(2):187-191. PubMed ID: 27882801 [TBL] [Abstract][Full Text] [Related]
40. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013. Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]